You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
Ahmad Tarhini
AUBMC
About Us
History
Mission and Vision
AUBMC Leadership Team
AUBMC Core Values
Why AUBMC?
Visiting AUBMC
Virtual Tours
External Medical Affairs (EMA)
Human Resources
Patient Care
Centers of Excellence
Specialized Clinical Programs and Services
Departments/Divisions
Nursing Services
Magnet Designation
Nurses’ Well-Being
Administrative Services
Patient Education
Research
Medical Research
Research Faculty
Education
Currently selected
AAHCI Mena Regional Office
Faculty of Medicine
Rafic Hariri School of Nursing
Continuing Medical Education (CME) Office
MyAUBHealth
Quick Links
Libraries
Visitors
International Patients
For Health Care Professionals
Halim & Aida Daniel ACC
A - Z
For Faculty and Staff
AUB
Hidden
Education
Currently selected
Home
Patient Care
Research
hremp
Naef K. Basile Cancer Institute (NKBCI)
Recent
Find a doctor
Search by Name
Search by Specialty
Please Select a Specialty
Search by Keyword
Find a Doctor
* Please type in name or select a speciality
Name
Specialty
Contact Information
Contact Us
+961-1-350000
PO Box: 11-0236
Riad El Solh, Beirut 1107 2020
Beirut - Lebanon
(More)
AUBMC
>
Education
Ahmad Tarhini, MD, PhD
Page Content
Professor of Medicine, Lerner School of Medicine of Case Western Reserve University. Director, Melanoma and Skin Cancer Program & Director, Center for Immuno-Oncology Research at Cleveland Clinic Taussig Cancer Institute.
Dr. Tarhini’s research includes clinical and translational investigations related to melanoma and areas of immunotherapy, targeted therapy and predictive and prognostic biomarker discovery. He currently leads or co-leads multiple national clinical trials including U. S. Intergroup E1609 and S1404 phase III adjuvant trials in melanoma. He has a major interest in the area of neoadjuvant therapy of melanoma where he reported promising data investigating CTLA4 blockade and PD1 blockade alone or in combination with cytokine therapy. Other ongoing efforts include research into overcoming resistance to immune checkpoint inhibitors including NCI10061 trial testing PD1 blockade with IL-12 in solid tumors. He is the Principal Investigator for the Experimental Therapeutics Clinical Trials Network (ETCTN) grant at Case Comprehensive Cancer Center (CCCC).
Before joining CCF and CCCC, Dr. Tarhini was a Tenured Associate Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh and Director of Clinical Sciences of the Pennsylvania Cancer Consortium. Dr. Tarhini has a Master of Science and a PhD in Clinical and Translational Science from the University of Pittsburgh School of Medicine (UPSOM).
Page Content 1